Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860108 | 0.83 | CYP4F2 (0.41) | CYP4F2CYP4A11AKT1RXRANR1H2 | |
| SCHEMBL3459340 | 0.82 | GRM2 (0.41) | SLC6A4SLC6A3LMNAHTTPDK2 | |
| SCHEMBL1577348 | 0.81 | SLC6A3 (0.44) | SLC6A4SLC6A3ADRA1AADRA1B | |
| SCHEMBL283 | 0.80 | SLC6A3 (0.48) | ACHESLC6A4SLC6A3 | |
| SCHEMBL16355870 | 0.80 | CYP4F2 (0.44) | CYP4F2CYP4A11AKT1RXRANR1H2 | |
| SCHEMBL3466168 | 0.80 | FOLH1 (0.55) | FOLH1HTT | |
| SCHEMBL18280658 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11AKT1ACHESLC6A4 | |
| SCHEMBL1069726 | 0.78 | FOLH1 (0.47) | CYP4F2CYP4A11AKT1ACHEFOLH1 | |
| SCHEMBL10433539 | 0.77 | KCNA5 (0.47) | AKT1ACHESLC6A4SLC6A3LMNA | |
| SCHEMBL18280518 | 0.77 | KCNA5 (0.41) | ACHEFOLH1SLC6A4SLC6A3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-8637562-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637562-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637562-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130109046-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109046-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120264223-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264223-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8232306-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232306-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232306-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100099134-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099134-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-22 | — | — | US | disclosed |
| WO-2010045420-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100099134-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-22 | — | — | US | disclosed |
| WO-2010045420-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | PPARG, CDK5, CDK5R1 | CYP4F2 3734/4885CYP4A11 1572/4885AKT1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.